PT-141

In plain English: PT-141 is a small synthetic peptide that nudges the brain's desire circuitry. Its official drug name is bremelanotide, and its brand name is Vyleesi. Unlike a pill that works on the plumbing of an erection, PT-141 works "upstream," on the wiring that generates the wish for sex in the first place.

PT-141 was discovered almost by accident. Researchers were testing melanotan II — a synthetic tanning peptide — when trial participants reported unexpected sexual arousal. Chemists then modified the molecule to focus its activity on the melanocortin-4 receptor (MC4R) and to reduce the skin-darkening effects of the parent compound, producing bremelanotide.^[7]

The U.S. Food and Drug Administration approved bremelanotide as Vyleesi on June 21, 2019, for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.^[10] "Acquired" means the low desire is a change from how the person used to be; "generalized" means it happens in all situations, not just with one partner or setting. The approved product is a single-dose, prefilled subcutaneous auto-injector delivering 1.75 mg.

Here is the part most marketing leaves out: that approval is narrow. Vyleesi is not FDA-approved for men, for postmenopausal women, or for general "libido enhancement." Research-grade vials of "PT-141" sold online for those purposes are unapproved for those uses. PT-141 is genuinely better-evidenced than most peptides — but only for one specific population and one specific problem.

The short version: PT-141 switches on melanocortin-4 receptors (MC4R) in the hypothalamus, a control center deep in the brain. Activating those receptors triggers downstream dopamine signaling in the circuits that drive sexual motivation. The result is meant to be more desire, generated centrally, rather than more blood flow generated locally.^[6]

This is a fundamentally different pathway from PDE5 inhibitors. Viagra (sildenafil) and Cialis (tadalafil) block an enzyme in the walls of blood vessels, letting more blood into the genitals so that an existing arousal signal can produce a physical response. They do nothing for desire itself. PT-141 targets the desire signal and depends on no vascular action at all.^[6]

The melanocortin system that PT-141 acts on is old, evolutionarily conserved, and involved in appetite, energy balance, skin pigmentation, and sexual behavior. Bremelanotide is a non-selective melanocortin agonist — it can touch several melanocortin receptors — but its pro-sexual effect is attributed principally to MC4R activation in the brain.^[8] Its activity at MC1R on pigment cells is also why skin darkening is a known, if less prominent than with melanotan II, side effect.

Feature	PT-141 (bremelanotide)	PDE5 inhibitors (Viagra/Cialis)
Target	Brain — MC4R in the hypothalamus	Blood vessels — the PDE5 enzyme
Effect	Increases desire and motivation	Increases genital blood flow
Approved use in women	Yes (premenopausal HSDD)	No
Route	Subcutaneous injection	Oral tablet
Timing	~45 minutes before, as-needed	30–60 minutes before (or daily for tadalafil)

Because the two mechanisms are independent, they are not directly interchangeable: a PDE5 inhibitor will not create desire, and PT-141 will not, by itself, guarantee the vascular response. This is exactly why the research community became interested in PT-141 for people whose problem is desire, not hardware.

The honest summary: PT-141 has real human trial data — a rarity for peptides — but the size of the benefit is modest, and the strongest evidence covers only premenopausal women. Below, each claim is laid out with its mechanism, the population studied, the effect size, and the limitation.

1. Low sexual desire in premenopausal women (the FDA-approved use)

Plain-English claim: PT-141 can produce a small but real improvement in sexual desire and a small reduction in the distress that low desire causes.

Mechanism: central MC4R activation driving pro-sexual dopaminergic pathways.^[6] Population: the pivotal evidence is the two RECONNECT Phase 3 randomized, double-blind, placebo-controlled trials (Studies 301 and 302), which together randomized 1,267 premenopausal women with acquired, generalized HSDD to either 1.75 mg subcutaneous bremelanotide as-needed or placebo over 24 weeks.^[1]

Effect size: both co-primary endpoints were statistically significant but small in absolute terms. On the integrated desire domain of the Female Sexual Function Index (FSFI), the bremelanotide group improved by about +0.35 points more than placebo; on the distress item of the Female Sexual Distress Scale (FSDS-DAO), distress fell by about -0.33 more than placebo (both P<.001).^[1] These are genuine drug effects — but they are modest, and writers and marketers who describe PT-141 as dramatically libido-boosting are overstating what the trials found.

Limitation: the benefit is measured on questionnaires, the average improvement is small, and roughly 18% of women in the trials stopped treatment because of side effects (mainly nausea). Subgroup and dose-finding analyses supported the consistency of the effect across the study population and the choice of the 1.75 mg dose.^[2][3][4]

2. Erectile dysfunction in men (off-label, older formulation)

Plain-English claim: in men who did not respond to Viagra, an older nasal-spray version of bremelanotide helped a meaningful minority.

Mechanism: the same central melanocortin pathway, engaging desire and arousal upstream of the vascular response.^[6] Population and effect size: the largest randomized male trial (Safarinejad 2008) gave 342 men with sildenafil-refractory erectile dysfunction 10 mg intranasal bremelanotide or placebo; 33.5% were positive responders versus 8.5% on placebo.^[5]

Limitation — read this carefully: that trial used a discontinued intranasal formulation at a much higher dose, not the approved 1.75 mg subcutaneous product. The intranasal program was halted in part over blood-pressure concerns. So while the male data is interesting and supports off-label interest, it is neither FDA-approved nor directly transferable to the injectable product people buy today. Any male use of PT-141 is off-label.

3. What PT-141 does not do

It is not a general "sexual enhancer" for people without a desire problem — no trial tested that, and it should not be sold that way. It is not a substitute for a PDE5 inhibitor when the issue is purely vascular. And it is not approved or well-studied in postmenopausal women; the RECONNECT trials deliberately enrolled premenopausal participants.^[1][9] For context on how PT-141 fits the broader category, see our peptides for sexual health overview.

Plain-English takeaway: the FDA-approved dose is one 1.75 mg subcutaneous injection, taken as-needed at least 45 minutes before anticipated sexual activity, no more than once in 24 hours and no more than 8 times per month. Those caps are not arbitrary — they exist to limit blood-pressure exposure and skin darkening.

Approved dosing (Vyleesi)

Parameter	Detail
Dose	1.75 mg
Route	Subcutaneous, abdomen or thigh
Timing	At least 45 minutes before anticipated activity
Max per day	1 dose in any 24-hour period
Max per month	8 doses
Trial of adequacy	Discontinue after 8 weeks if no improvement

The approved product is a single-use, prefilled auto-injector, so patients using Vyleesi never handle a vial or measure a dose.^[10]

Research-grade vials and the reconstitution math

Research-grade "PT-141" is sold as a lyophilized (freeze-dried) powder that must be reconstituted with bacteriostatic water before use — and this is where people make dosing errors. Note that any such use for sexual enhancement is unapproved; the approved product is the auto-injector above.

Worked example. Suppose you have a 10 mg vial and you add 2 mL of bacteriostatic water:

• Concentration = 10 mg ÷ 2 mL = 5 mg/mL, i.e. 5,000 mcg per mL.
• To draw the approved 1.75 mg (1,750 mcg): 1,750 ÷ 5,000 = 0.35 mL, which is 35 units on a standard U-100 insulin syringe.
• A research dose of 1 mg (1,000 mcg) would be 1,000 ÷ 5,000 = 0.20 mL, or 20 units.

Use the peptide calculator to check these numbers for your own vial size and water volume, and see the reconstitution guide for sterile technique. Research protocols cited for the injectable form typically fall in the 1–2 mg subcutaneous range, dosed 45–60 minutes before activity — but the approved, tested dose is 1.75 mg.

Onset, duration, and cycling

Effects generally begin within 45 minutes to an hour and can last several hours. Because PT-141 is taken as-needed rather than on a daily schedule, there is no "cycle" in the bodybuilding sense — but the monthly cap still applies. Do not exceed 8 doses per month or dose more than once in 24 hours, regardless of formulation, because both blood-pressure and pigmentation risks are cumulative with frequency.^[10]

Storage

• Vyleesi auto-injectors: store at room temperature (20–25°C).
• Lyophilized research vials: refrigerate at 2–8°C, or freeze for long-term storage.
• Reconstituted solution: refrigerate at 2–8°C and use within about 28 days; do not freeze.

Plain-English takeaway: PT-141 has the best-characterized safety profile of almost any peptide on this site — because it went through full FDA Phase 3 trials — but "well-characterized" does not mean "mild." Nausea is very common, blood pressure rises transiently after every dose, and frequent use can darken the skin. Used within the FDA's limits and with blood-pressure screening, it is generally tolerable; used outside them, the risks climb.

Frequency-grouped side effects (from the RECONNECT Phase 3 trials)

Effect	Frequency	Notes
Nausea	~40%	Dose-limiting and the leading reason people stop; often worst on the first few doses and eases with time. Each of nausea, flushing, and headache occurred in ≥10% of treated patients in both trials.[1]
Flushing	~20%	Facial and body warmth from melanocortin receptor activation
Injection-site reactions	~13%	Mild redness or soreness; usually transient
Headache	~11%	Often resolves with subsequent doses
Vomiting	~5%	Usually tied to severe nausea
Transient blood-pressure increase	After every dose	Peaks 2–4 hours post-dose with a small parallel drop in heart rate; small in healthy people, meaningful in cardiovascular disease[10]
Hyperpigmentation (skin darkening)	Frequency-dependent	More likely with frequent dosing and in darker skin; may not fully reverse. Basis for the ≤8 doses/month cap[10]
Discontinuation due to side effects	~18%	Mostly nausea-driven

Most adverse events in the trials were mild to moderate.^[1] A recent expert review reaches the same overall picture: real efficacy in the approved population, with tolerability — chiefly nausea — as the main limiting factor.^[8]

Blood pressure and the cardiovascular caution

PT-141 causes a transient rise in blood pressure after each dose, peaking around 2–4 hours later, with a small decrease in heart rate over the same window.^[10] In healthy people these shifts are small. In people with cardiovascular disease they can matter. The FDA label makes Vyleesi contraindicated in uncontrolled hypertension or known cardiovascular disease. It is prudent to check blood pressure before starting, and to avoid dosing within a few hours of activities that demand full alertness given the combination of flushing, nausea, and BP change.

Hyperpigmentation: why the FDA caps it at 8 doses a month

Because PT-141 also touches melanocortin receptors on pigment cells, frequent dosing can cause cumulative skin darkening — focal spots on the face, gums, or breasts, darkening of existing moles, or generalized pigmentation. This is the reason the Vyleesi label sets a maximum of 8 doses per month and at least 24 hours between doses.^[10] Risk is higher in darker skin (Fitzpatrick IV–VI) and with pre-existing nevi, and it may not fully reverse on stopping. Any new or changing mole in a melanocortin-peptide user should be evaluated by a dermatologist. See our Melanotan II page for more on this receptor class.

Contraindications, interactions, and who should avoid it

• Uncontrolled hypertension or known cardiovascular disease — an FDA contraindication.
• Naltrexone: the FDA label warns that bremelanotide can lower naltrexone plasma exposure, which may compromise naltrexone's effectiveness for opioid or alcohol use disorder. Do not combine.^[10]
• Pregnancy and breastfeeding: not recommended.
• Other melanocortin peptides (melanotan I/II): do not stack — additive pigmentation and blood-pressure risk.
• Slowed gastric emptying: PT-141 can delay stomach emptying, which may affect the absorption of oral medications taken around the same time.^[10]

What to do if you have side effects

• Persistent nausea: it often eases over the first few doses; some clinicians use an antiemetic beforehand off-label. If it stays severe, reconsider use.
• Blood-pressure elevation: stop and have it evaluated; do not resume if cardiovascular risk is confirmed.
• Skin darkening or a changing mole: reduce frequency or stop, and get any new or changing mole checked promptly.
• Severe headache or vision change after dosing: seek emergency care to rule out a hypertensive emergency.

For broader context, see Are Peptides Safe? and our sexual health overview.

Plain-English takeaway: PT-141 is unusual because a real, FDA-approved version exists (Vyleesi, by prescription) alongside an unregulated "research chemical" market. Those are not the same product, and the quality gap matters.

The legal reality

• Vyleesi (bremelanotide) is an FDA-approved prescription drug for premenopausal women with HSDD. It is a manufactured, quality-controlled auto-injector.^[10]
• Research-grade "PT-141" sold online is not FDA-approved for any use, is labeled "not for human consumption," and is unregulated. Using it for men, for postmenopausal women, or for general enhancement is off-label or unapproved.
• PT-141 is not a DEA-controlled substance, but that is not the same as being approved or quality-assured.

What to look for in a research product

• Batch-specific Certificate of Analysis (COA): HPLC purity (look for ≥98%) and mass-spectrometry identity, tied to the exact lot you are buying — not a generic sample COA.
• Endotoxin testing for anything intended for injection.
• Proper packaging: lyophilized powder in sealed, light-protected vials.

Red flags

• No COA, or a COA from the seller rather than an independent lab.
• Pre-mixed liquid "PT-141" — shorter shelf life and higher contamination risk than lyophilized powder.
• Prices far below market, or "for human use" and explicit sexual-enhancement claims, which signal a non-compliant vendor.

Bottom line: the only version of PT-141 with proven quality and proven efficacy is the FDA-approved prescription product, and even that is proven only for one specific population. For everything else, the honest framing is "unapproved research compound." See Are Peptides Legal? for the full legal picture.